TGF-βs and TGF-β receptors in atherosclerosis

Cytokine and Growth Factor Reviews

Volumn 11, Issue 1-2, 2000, Pages 103-114

  McCaffrey, Timothy A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; ACTIVIN RECEPTOR 1; PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CAROTID ARTERY; CELL PROLIFERATION; CORONARY ARTERY; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; HYPERPLASIA; NONHUMAN; RECEPTOR DENSITY; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WOUND HEALING; ANGIOPLASTY; ANIMAL; ARTERIOSCLEROSIS; CYTOSKELETON; DRUG EFFECT; EXTRACELLULAR MATRIX; GENETICS; METABOLISM; METHODOLOGY; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STENOSIS, OCCLUSION AND OBSTRUCTION; VASCULAR ENDOTHELIUM;

ACTIVIN RECEPTORS, TYPE I; AGING; ANGIOPLASTY; ANIMALS; ARTERIOSCLEROSIS; CONSTRICTION, PATHOLOGIC; CYTOSKELETON; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; MUTATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033622125     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(99)00034-9     Document Type: Review

References (66)

1. National Center for Health Statistics. Deaths: Final Data for 1997. Vol. 47, No. 19. 108, 1999. pp. (PHS) 99-1120
2. Atherosclerosis of the aorta and coronary arteries in five towns. Bulletin of the World Health Organization 1976;53(5-6):485-645
3. Herrman J.-P.R., Hermans W.R.M., Vos J., Serruys P.W. Pharmacological approaches to the prevention of restenosis following angioplasty: The search for the Holy Grail? (Part I). Drugs. 46:1993;18-52.
4. Volteas N., Labropoulos N., Leon M., Kalodiki E., Chan P., Nicolaides A.N. Risk factor associated with recurrent carotid stenosis. IntAngiol. 13:(2):1994;143-147.
5. Leimgruber P.P., Roubin G.S., Hollman J., Cotsonis G.A., Meier B., et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation. 73:1986;710-717.
6. Serruys P.W., Herrman J.P., Simon R., Rutsch W., Bode C., Laarman G.J., et al. A comparison of hirudin with heparin in the prevention of retenosis after coronary angioplasty. Helvetica Investigators. N. Engl. J. Med. 333:(12):1995;757-763.
7. The E.R.A.S.E.R. Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 100:1999;799-806.
8. Bochaton-Piallat M.L., Gabbiani F., Redard M., Desmouliere A., Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am. J. Pathol. 146:(5):1995;1059-1064.
9. Stemerman M.B., Weinstein R., Rowe J.W., Maciag T., Fuhro R., Gardner R. Vascular smooth muscle cell growth kinetics in vivo in aged rats. Proc. Natl. Acad. Sci. USA. 79:1982;3863-3866.
10. Hariri R.J., Alonso D.R., Hajjar D.P., Coletti D., Weksler M.E. Aging and atherosclerosis I. Development of myointimal hyperplasia after endothelial injury. J. Exp. Med. 164:1986;1171-1178.
11. Hariri R.J., Hajjar D.P., Coletti D., Alonso D.R., Weksler M.E., Rabellino E. Aging and atherosclerosis. Cell cycle kinetics of young and old arterial smooth muscle cells. Am. J. Pathol. 131:1988;132-136.
12. Mehta V.Y., Jorgensen M.B., Raizner A.E., Wolde-Tsadik G., Mahrer P.R., Mansukhani P. Spontaneous regression of restenosis: an angiographic study. J. Am. Coll. Cardiol. 26:1995;696-702.
13. Rembold C. Could atherosclerosis originate from defective smooth muscle cell death? Persp. Biol. Med. 39:(3):1996;405-408.
14. Lyons R.M., Gentry L.E., Purchio A.F., Moses H.L. Mechanism of activation of latent recombinant transforming growth factor-β1 by plasmin. J. Cell Biol. 110:1990;1361-1367.
15. Lawrence D.A., Pircher R., Kryceve-Martineri C., Jullien P. Normal embryo fibroblasts release transforming growth factors in a latent form. J. Cell Physiol. 121:1984;184-188.
16. Lyons R.M., Keski-Oja J., Moses H.L. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J. Cell Biol. 106:1988;1659-1665.
17. Kojima S., Nara K., Rifkin D.B. Requirement for transglutaminase in the activation of latent transforming growth factor-β in bovine endothelial cells. J. Cell Biol. 121:1993;439-448.
18. Schultz-Cherry S., Lawler J., Murphy-Ullrich J.E. The Type 1 repeats of thrombospondin 1 activate latent transforming growth factor-β J. Biol. Chem. 269:(43):1994;26783-26788.
19. Mooradian D.L., Lucas R.C., Weatherbee J.A., Furcht L.T. Transforming growth factor-β1 binds to immobilized fibronectin. J. Cell Biochem. 41:1989;189-200.
20. Murphy-Ullrich J.E., Schultz-Cherry S., Hook M. Transforming growth factor-β complexes with thrombospondin. Mol. Biol. Cell. 3:1992;181-188.
21. Paralkar V.M., Vukicevic S., Reddi A.H. Transforming growth factor-β type 1 binds to collagen IV of basement membrane matrix: Implications for development. Dev. Biol. 143:1991;303-308.
22. Flanders K.C., Thompson N.L., Cissel D.S., Van Obberghen-Schilling E., Baker C.C., Kass M.E., et al. Transforming growth factor-β1: Histochemical localization with antibodies to different epitopes. J. Cell Biol. 108:1989;653-660.
23. Falcone D.J., McCaffrey T.A., Haimovitz-Friedman A., Vergilio J.A., Nicholson A.C. Macrophage and foam cell release of matrix bound growth factors: role of plasminogen activation. J. Biol. Chem. 268:(16):1993;11951-11958.
24. McCaffrey T.A., Falcone D.J., Du B. Transforming growth factor-β is a heparin-binding protein: Identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-β1. J. Cell Physiol. 152:1992;430-440.
25. *2-macroglobulin inactive complex. J. Cell Biol. 109:1989;441-448.
26. Grainger D.J., Witchell C.M., Watson J.V., Metcalfe J.C., Weissberg P.L. Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor β-like activity from serum. Cardiovasc. Res. 27:1993;2238-2247.
27. Nikol S., Isner J.M., Pickering J.G., Kearney M., Leclerc G., Weir L. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J. Clin. Invest. 90:1992;1582-1592.
28. Majesky M.W., Lindner V., Twardzik D.R., Schwartz S.M., Reidy M.A. Production of transforming growth factor-β1 during repair of arterial injury. J. Clin. Invest. 88:1991;904-910.
29. Wolf Y.G., Rasmussen L.M., Ruoslahti E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J. Clin. Invest. 93:(3):1994;1172-1178.
30. Saltis J., Agrotis A., Bobik A. Regulation and interactions of transforming growth factor-beta with cardiovascular cells: implications for development and disease. Clin. Exp. Pharmacol. Physiol. 23:1996;193-200.
31. Heimark R.L., Twardizik D.R., Schwartz S.M. Inhibition of endothelial regeneration by type-β transforming growth factor from platelets. Science. 233:1986;1078-1080.
32. Bell J.A., Bell L. Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells. Circ. Res. 65:1989;1057-1065.
33. Chen J.K., Hoshi H., McKeehan W.L. Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA. 84:1987;5287-5291.
34. Madri J.A., Reidy M.A., Kocher O., Bell L. Endothelial cell behavior after denudation injury is modulated by transforming growth factor-β1 and fibronectin. Lab. Invest. 60:1989;755-764.
35. 1 on in vitro angiogenesis. Exp. Cell Res. 204:1993;356-363.
36. Assoian R.K., Sporn M.B. Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J. Cell Biol. 102:1986;1217-1223.
37. Bjorkerud S. Effects of transforming growth factor-β1 on human arterial smooth muscle cells in vitro. Arteriosclerosis. 11:1991;892-902.
38. Battegay E.J., Raines E.W., Seifert R.A., Bowen-Pope D.F., Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 63:1990;515-524.
39. Topouzis S., Majesky M.W. Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta. Dev. Biol. 178:1996;430-445.
40. Pollman M., Naumovski L., Gibbons G. Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-β1 in endothelial cells versus smooth muscle cells. Circulation. 99:1999;2019-2026.
41. Bennett M.R., Littlewood T.D., Schwartz S.M., Weissberg P.L. Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis. Circ. Res. 81:1997;591-599.
42. McCaffrey T., Du B., Bray P., Fu C., Sanborn T., Deutsch E., et al. The expression of TGF-β receptors in human atherosclerosis: evidence for acquired resistance due to receptor imbalance. J. Mol. Cell Cardiol. 31:1999;1627-1642.
43. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 334:1988;260-262.
44. Falcone D.J., McCaffrey T.A., Haimovitz-Friedman A., Garcia M. Transforming growth factor-β1 stimulates macrophage urokinase expression and release of matrix bound basic fibroblast growth factor. J. Cell Physiol. 155:1993;595-605.
45. Ross R., Masuda J., Raines E.W., Gown A.M., Katsuda S., Sasahara M., et al. Localization of PDGF-B protein in macrophages in all stages of atherogenesis. Science. 248:1990;1009-1012.
46. Lomo J., Blomhoff H.K., Beiske K., Stokke T., Smeland E.B. TGF-β1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J. Immunol. 154:(4):1995;1634-1643.
47. Nabel E.G., Shum L., Pompili V.J., Yang Z.-Y., San H., Shu H.B., et al. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc. Natl. Acad. Sci. USA. 90:1993;10759-10763.
48. Kanzaki T., Tamura K., Takahashi K., Saito Y., Akikusa B., Oohashi H., et al. In vivo effect of TGF-β1: enhanced intimal thickening by administration of TGF-β1 in rabbit arteries injured with a balloon catheter. Arterioscler. Thromb. 15:1995;1951-1957.
49. Grainger D.J., Kemp P.R., Liu A.C., Lawn R.M., Metcalfe J.C. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature. 370:1994;460-462.
50. Sarzani R., Brecher P., Chobanian A.V. Growth factor expression in aorta of normotensive and hypertensive rats. J. Clin. Invest. 83:1989;1404-1408.
51. Bobik A., Agrotis A., Kanellakis P., Dilley R., Krushinsky A., Smirnov V., et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation. 99:1999;2883-2891.
52. McCaffrey T.A., Nicholson A.C., Szabo P.E., Weksler M.E., Weksler B.B. Aging and Arteriosclerosis: The increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity. J. Exp. Med. 167:1988;163-174.
53. Bochaton-Piallat M.-L., Gabbiani F., Ropraz P., Gabbiani G. Age influences the replicative activity and the differentiation features of cultured rat aortic smooth muscle cell populations and clones. Arterioscler. Thromb. 13:1993;1449-1455.
54. McCaffrey T.A., Falcone D.J. Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-β in vascular smooth muscle cells. Mol. Biol. Cell. 4:1993;315-322.
55. Saltis J., Agrotis A., Kanellakis P., Bobik A. Developmentally regulated transforming growth factor-beta 1 action on vascular smooth muscle growth in the SHR. Clin. Exp. Pharmacol. Physiol. 21:1994;149-152.
56. Narhi L.O., Kenney W.C., Prestrelski S.J., Arakawa T., Lyons D., Lary J., Yphantis D.A. Conformation of glutathione adduct and oxidized forms of platelet-derived growth factor. Int. J. Pept. Protein Res. 41:1993;8-14.
57. McCaffrey T.A., Consigli S., Du B., Falcone D.J., Sanborn T.A., Spokojny A.M., Bush H. Decreased Type II/Type I TGF-β1 receptor ratio in cells derived from human atherosclerotic lesions: conversion from an antiproliferative to profibrotic response to TGF-β1. J. Clin. Invest. 96:1995;2667-2675.
58. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 8:1997;171-179.
59. Chen R.H., Ebner R., Derynck R. Inactivation of the Type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science. 260:1993;1335-1338.
60. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L.Z., Lutterbaugh J., et al. Inactivation of the Type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
61. McCaffrey T., Du B., Consigli S., Szabo P., Bray P., Hartner L., et al. Genomic instability in the Type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J. Clin. Invest. 100:1997;2182-2188.
62. Choi S.G., Yi Y., Kim Y.S., Kato M., Chang J., Chung H.W., et al. A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor. J. Biol. Chem. 273:1998;110-117.
63. Humphries D.E., Bloom B.B., Fine A., Goldstein R.H. Structure and expression of the promoter for the human type II transforming growth factor-Beta receptor. Biochem. Biophys. Res. Commun. 203:1994;1020-1027.
64. Bae H., Geiser A., Kim D., Chung M., Burmester J., Sporn M., et al. Characterization of the promoter region of the human transforming growth factor-β Type II receptor gene. J. Biol. Chem. 270:1995;29460-29468.
65. Ammanamanchi S., Kim S.J., Sun L.Z., Brattain M.G. Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2′-deoxycytidine. J. Biol. Chem. 273:1998;16527-16534.
66. Bray P., Du B., Mejia V., Hao S., Deutsch E., Fu C., et al. Glucocorticoid resistance due to reduced expression of the glucocorticoid receptor and heat shock protein 90 in cells from human vascular lesions. Arterioscler. Thromb. Vasc. Biol. 19:1999;1180-1189.